On February 12, 2026, PTC Therapeutics, Inc. announced the withdrawal of its New Drug Application resubmission for Translarna™ for treating a specific type of Duchenne muscular dystrophy due to FDA feedback. This event is deemed significant for the company from an equity investor perspective.